Dayton, OH Clinical Trials

A listing of Dayton, OH Clinical Trials actively recruiting patient volunteers.

Search by Name
Search
Filter by Condition
264 trials found

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

NCT05540522

This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.

Conditions: Influenza, Human

Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

NCT05516992

The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.

Conditions: Lumbar Degenerative Disc Disease

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

NCT05468736

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses and a booster dose of NVX CoV2373 given 21 days apart in pediatric participants (3 age cohorts; 6 to < 12 years, 2 to < 6 years, and 6 to < 24 months of age). Each age cohort will be conducted in 2 parts starting with the oldest age cohort (6 to < 12 years of age).

Conditions: COVID-19
Phase: Phase 2/3

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

NCT05463731

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).

Conditions: Alzheimer's Disease

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05455684

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Conditions: Depressive Disorder, Major, Anhedonia

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

NCT05456529

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

Conditions: Atopic Dermatitis (AD)

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

NCT05451810

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or R/R follicular lymphoma (FL). Adverse events will be assessed. Epcoritamab is an investigational drug being developed for the treatment of ...

Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

NCT05414422

This is a double-blind, randomized, placebo-controlled, multicenter study comprised of 3 phases:screening (up to 2 weeks [Day -15 to Day -2]), In-Clinic Treatment (Day -1 to Day 2; including double-blind treatment [Day 1]), and post-treatment follow-up (7 and 14 days after infusion on Days 8 and 15, respectively). A total of 93 adult subjects with TRD will be randomly allocated in equal cohorts of 31 subjects/arm to the 3 arms of the study in a blinded manner.

Conditions: Treatment Resistant Depression

Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.

NCT05372315

To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) with or without iStent/Hydrus/Goniotomy when placed in the lower punctum compared to the upper punctum.

Conditions: Cataract

Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure

NCT05355974

The purpose of this study is to investigate whether protocolized vasopressor use for patients with normal blood pressure undergoing rapid sequence intubation improves hemodynamic parameters and mitigates adverse events. The hypothesis is that use of vasopressors during Rapid Sequence Intubation will prevent substantial decreases in blood pressure when compared to normal intravenous fluids.

Conditions: Respiratory Failure, Hypotension and Shock, Hypotension on Induction, Intubation Complication, Anesthesia Intubation Complication

A Study to Evaluate the Continuous Safety and Efficacy of BIIB059 in Adults With Active Systemic Lupus Erythematosus

NCT05352919

The primary objective of this study is to evaluate the long-term safety and tolerability of BIIB059 in participants with active systemic lupus erythematosus (SLE). The secondary objectives of this study are to evaluate the long-term effect of BIIB059 on disease activity in participants with SLE, to evaluate the long-term effect of BIIB059 in participants with SLE in maintaining low disease activity, to evaluate the effect of BIIB059 in participants with active SLE in preventing irreversible org ...

Conditions: Systemic Lupus Erythematosus (SLE)

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjögren's Syndrome

NCT05350072

A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren's syndrome (NEPTUNUS-1)

Conditions: Sjogren Syndrome